Ketamine therapy, once confined to emergency rooms and anesthesia carts, is now a fixture in the treatment landscape for depression, anxiety, and PTSD. Yet the path to coverage remains narrow. Private insurers deny roughly 40 to 60 percent of claims for off-label ketamine infusions, according to a 2024 survey by the Ketamine Therapy Research Consortium and a 2025 analysis by the Depression and Bipolar Support Alliance. As of late 2024, no uniform standard governs reimbursement, leaving patients to face inconsistent policies that often end in rejection.

The rise in denials mirrors the growth of off-label use. A 2025 analysis by the Ketamine Therapy Research Consortium found that the number of US clinics offering intravenous ketamine for mental health indications increased by roughly 30 percent over the prior year. Most insurers, however, still classify the treatment as experimental. Their medical policies cite the absence of large-scale randomized controlled trials for depression, anxiety, or PTSD — indications for which the FDA has not approved ketamine. The result is a coverage gap that forces patients to pay $400 to $800 per infusion out-of-pocket, often for a course of six to eight sessions.

For a typical patient with treatment-resistant depression, a full induction course can cost $4,000 to $6,400, with maintenance infusions adding hundreds per month. Some clinics offer sliding-scale fees or financial assistance, but the burden falls disproportionately on those without employer-sponsored plans that cover mental health services. The trend parallels broader disparities in healthcare access, as seen in mental health access disparities by income in US metro areas.

How payer medical policies define “medically necessary”

Insurance coverage for ketamine therapy hinges on a single phrase: “medically necessary.” Each plan defines it differently, but common threads run through most policies. Typically, a patient must have failed at least two adequate trials of standard antidepressants from different classes. Some policies also require a documented history of treatment-resistant depression, defined as a lack of response to four or more medications or to electroconvulsive therapy (ECT).

Even when these criteria are met, prior authorization is almost always required. The process demands a detailed letter from the prescribing physician, including the patient’s diagnosis, past treatments, and justification for off-label use. Many plans also mandate a peer-to-peer review, where the treating clinician discusses the case with a medical director employed by the insurer. These reviews can be adversarial, with physicians reporting that reviewers often default to “not FDA-approved” as a denial reason.

One notable exception is intranasal esketamine (Spravato), which the FDA approved in 2019 for treatment-resistant depression. Spravato is covered by many commercial plans, but with strict limitations. Patients must receive it in a certified treatment center and be monitored for two hours after each dose. The drug’s high list price — roughly $600 to $900 per session — and the requirement for in-clinic administration limit its reach. Fewer than 2,000 centers nationwide offer Spravato as of 2025, concentrated in metropolitan areas.

For intravenous ketamine, insurers argue that without FDA approval, the evidence base is insufficient to justify coverage. They point to the lack of comparative effectiveness data against established treatments like ECT or transcranial magnetic stimulation (TMS). A 2024 review in the American Journal of Psychiatry noted that while short-term response rates for ketamine infusions range from 50 to 70 percent in controlled settings, relapse within four to six weeks occurs in 50 to 80 percent of patients without maintenance therapy. This high relapse rate, insurers say, makes the cost-benefit calculus unfavorable.

Patient advocacy groups push for coverage mandates

Dissatisfied with voluntary insurer policies, patient advocacy groups have turned to state legislatures. The Ketamine Advocacy Network (KAN), a nonprofit founded in 2022, has lobbied for bills in California, New York, and Texas that would require insurers to cover off-label ketamine therapy for mental health conditions on par with FDA-approved treatments. The proposed legislation draws on mental health parity laws, arguing that denying coverage for ketamine while covering Spravato creates an arbitrary distinction.

“Patients are being told they have to fail on Spravato before we’ll consider ketamine, even though the evidence for IV ketamine is stronger for some populations,” said a KAN spokesperson in a 2025 interview with STAT. “That’s not evidence-based medicine; it’s cost-shifting.” The group has commissioned its own meta-analysis of 18 randomized trials, which it says shows that intravenous ketamine produces clinically meaningful improvements in depressive symptoms within 24 hours, a speed unmatched by oral antidepressants.

Insurance lobbyists have pushed back, arguing that mandates would raise premiums. A course of six ketamine infusions costs $2,400 to $4,800 at typical clinic rates; if 1 percent of commercially insured adults with depression sought treatment, the annual system-wide cost could exceed $10 billion, according to an analysis by the American Health Insurance Plans. They also note that state mandates would not apply to self-funded employer plans, which cover roughly 60 percent of insured workers, limiting the impact of any single state law.

As of early 2026, none of the proposed bills have passed. California’s SB-1044, introduced in 2024, died in committee after heavy opposition from the insurance industry. A revamped version in New York is pending, with hearings scheduled for mid-2026. Advocacy groups are also exploring federal avenues, including a petition to the FDA to expand the label for ketamine to include treatment-resistant depression, but agency action is not expected soon.

The debate mirrors earlier fights over coverage for TMS and ECT, both of which faced insurer resistance before becoming standard. However, ketamine’s off-label status and its potential for abuse — dissociative side effects and a small risk of cystitis with long-term use — make the political calculus more complicated.

Clinical evidence gap fuels insurer skepticism

Insurers’ skepticism is not without foundation. The clinical evidence for ketamine in mental health, while promising, is incomplete. Most randomized trials have followed patients for only four to six weeks, and few have compared ketamine head-to-head against active treatments like ECT or TMS. A 2023 meta-analysis of 28 studies found that ketamine produced a rapid reduction in suicidal ideation, but the effect diminished after two weeks. Long-term data are sparse: only a handful of studies have tracked patients beyond six months, and those report relapse rates of 50 to 80 percent without maintenance therapy.

Dosing protocols also vary widely. Some clinics use a fixed dose of 0.5 mg per kilogram infused over 40 minutes, while others adjust based on response or tolerate higher doses. There is no consensus on optimal frequency — weekly, biweekly, or monthly maintenance — and no biomarker to predict who will respond. This variability makes it difficult for insurers to define a standard course of treatment, a prerequisite for coverage decisions.

Adverse effects add another layer of caution. Dissociation during infusion is common, occurring in 30 to 50 percent of patients, though it typically resolves within an hour. Blood pressure spikes require monitoring, and a small number of patients develop cystitis or cognitive impairment with repeated use. The FDA has issued a warning about the risks of compounding pharmacies supplying ketamine for off-label use, and several clinics have been cited for unsafe practices.

“We’re not saying ketamine doesn’t work for some patients,” said a medical director at a large national insurer in a 2025 trade publication. “But we need to see data that show it works better than what we already cover, and that the benefits last. Right now, the evidence supports short-term use in a subset of patients, but not the widespread expansion we’re seeing.”

Proponents counter that the evidence for other covered treatments is also limited. ECT, for example, has never been tested in a placebo-controlled trial, yet it is widely covered. TMS is approved based on trials that showed modest effect sizes. They argue that the bar for ketamine is higher because it is not FDA-approved for mental health, creating a Catch-22: without coverage, large-scale trials are hard to fund; without trials, coverage remains elusive.

Out-of-pocket model creates equity divide

The reliance on out-of-pocket payment has created a two-tiered system. Patients who can afford $400 to $800 per infusion gain access to a treatment that may relieve severe depression within hours. Those who cannot often go without, cycling through medications that take weeks to work or cause intolerable side effects. A 2025 survey by the Depression and Bipolar Support Alliance found that 40 percent of respondents who tried to access ketamine therapy were unable to afford it.

Clinics cluster in affluent urban areas. A 2024 analysis by the RAND Corporation found that 70 percent of US ketamine clinics are located in counties with median household incomes above the national average. Rural and low-income areas have few or no options. The same analysis noted that clinics in majority-Black or Hispanic neighborhoods are less likely to offer sliding-scale fees or accept Medicare, which rarely covers off-label use.

Medicare and Medicaid coverage for ketamine therapy is virtually nonexistent. The Centers for Medicare & Medicaid Services (CMS) does not cover off-label ketamine for mental health, classifying it as investigational. Some state Medicaid programs have begun covering Spravato, but the requirement for in-clinic administration and prior authorization limits uptake. The Veterans Health Administration has piloted ketamine for PTSD in a handful of centers, but the program is small and not widely available.

The equity divide is stark. A 2026 study in Health Affairs found that patients in the top income quartile were four times more likely to receive ketamine therapy than those in the bottom quartile, after adjusting for clinical severity. The authors noted that this disparity mirrors patterns seen in other high-cost treatments, such as healthcare access disparities by income in the US, where access tracks wealth rather than need.

Advocates argue that coverage mandates would narrow this gap, but insurers warn that mandating coverage without addressing cost could lead to premium increases that disproportionately hurt lower-income enrollees. The trade-off between access and affordability remains unresolved.

Appeals process offers limited relief

For patients who receive a denial, the appeals process is often the only recourse. Yet the odds are stacked against them. Industry data suggest that fewer than 10 percent of denials for off-label ketamine therapy are overturned on internal appeal. External review, available in some states, yields slightly higher success rates, but the process is lengthy and requires substantial documentation.

A typical appeal involves submitting a letter from the treating physician, copies of relevant medical records, and published studies supporting the use of ketamine for the patient’s condition. Some insurers require a second peer-to-peer review, and many have strict deadlines that can be missed if paperwork is delayed. The average time from denial to resolution is four to eight weeks, during which patients often abandon treatment or pay out-of-pocket to continue.

“I spent two months on an appeal for a patient who had failed seven antidepressants and ECT,” said a psychiatrist at a major academic medical center in a 2025 interview. “The insurer still denied it, citing lack of FDA approval. The patient ended up paying $3,200 for the course. That’s not a system that works for anyone.”

State external review programs, which allow an independent third party to evaluate the claim, can override insurer decisions. However, these programs vary widely. In California, for example, external review is available only for denials based on medical necessity, not for exclusions of experimental treatment. In New York, the process is more robust, but it applies only to fully insured plans, not self-funded ones.

Some patients have turned to litigation. A class-action lawsuit filed in 2025 against a major insurer alleges that the company systematically denies claims for ketamine therapy without individualized medical review, in violation of state mental health parity laws. The case is pending, and its outcome could set a precedent for how insurers handle off-label treatments.

The appeals process, while theoretically a safety net, is a poor substitute for coverage. For many patients, the time, cost, and emotional toll of fighting a denial outweigh the potential benefit. As one patient advocacy group put it, “The system is designed to wear you down.”

Looking ahead, the path to broader coverage may depend on a combination of legislative action, clinical trial results, and payer innovation. Some insurers have begun to cover ketamine therapy on a case-by-case basis, often after multiple appeals or physician pressure. Meanwhile, the Ketamine Therapy Research Consortium has launched a multi-site registry to collect long-term outcomes data, which could strengthen the evidence base. Advocacy groups are also exploring federal avenues, including a petition to the FDA to expand the label for ketamine to include treatment-resistant depression. While agency action is not expected soon, the momentum suggests that the conversation around off-label coverage is far from over. For patients, the message is clear: persistence, documentation, and advocacy remain essential in navigating a system that has yet to catch up with the science.

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Readers should consult their healthcare provider and insurer for guidance on treatment options and coverage.